Impel Pharmaceuticals Inc Revenue Growth Rates (IMPL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Impel Pharmaceuticals Inc   (NASDAQ: IMPL)
 

IMPL's Revenue Growth by Quarter and Year

Impel Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMPL Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 4.79
2nd Quarter June 6.36
1st Quarter March 4.37
FY 15.52





IMPL Revenue third quarter 2023 Y/Y Growth Comment
Impel Pharmaceuticals Inc reported Revenue rise of 55.62% year on year in the third quarter 2023, to $ 4.79 millions, this is lower than Impel Pharmaceuticals Inc 's recent average Revenue surge of 904.48%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue growth. While Impel Pharmaceuticals Inc ' s Revenue jump of 55.62% ranks overall at the positon no. 328 in the third quarter 2023.


IMPL Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 763.79 % - -
3rd Quarter September 55.62 % 3322.22 % - -
2nd Quarter June 127.14 % - - -
1st Quarter March 148.3 % - - -
FY   - 1788.06 % - -

Financial Statements
Impel Pharmaceuticals Inc 's third quarter 2023 Revenue $ 4.79 millions IMPL's Income Statement
Impel Pharmaceuticals Inc 's third quarter 2022 Revenue $ 3.08 millions Quarterly IMPL's Income Statement


IMPL Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 62.66 % 544.44 % -
3rd Quarter September -24.64 % 10 % - -
2nd Quarter June 45.54 % 59.09 % - -
1st Quarter March -12.77 % 203.45 % - -
FY (Year on Year)   - 1788.06 % - -


Back to IMPL Growth rate Comparisons >> Back to IMPL Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #128
Overall #328

Revenue Y/Y Growth Statistics
High Average Low
3286.81 % 904.48 % 55.52 %
(Sep 30 2022)   (Sep 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #128
Overall #328
Revenue Y/Y Growth Statistics
High Average Low
3286.81 % 904.48 % 55.52 %
(Sep 30 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Impel Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
534.07 % 138.18 % -24.69 %
(Dec 31 2021)  


IMPL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Impel Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -24.64% to $ 4.79 millions, from $ 6.36 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Revenue quarter on quarter growth. While Impel Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3754.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #210
Healthcare Sector #576
Overall #3754
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #210
Healthcare Sector #576
Overall #3754
Revenue Q/Q Growth Statistics
High Average Low
534.07 % 138.18 % -24.69 %
(Dec 31 2021)  


IMPL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Impel Pharmaceuticals Inc disclosed fall in Revenue from the second quarter by -24.64% to $ 4.79 millions, from $ 6.36 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Revenue quarter on quarter growth. While Impel Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3754.


Impel Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 20.54 $ 18.83 $ 15.27 $ 12.65 $ 8.22
Y / Y Revenue Growth (TTM) 149.81 % 259.96 % - - -
Year on Year Revenue Growth Overall Ranking # 706 # 796 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 9.09 % 23.33 % 20.65 % 53.9 % 57.19 %
Seq. Revenue Growth (TTM) Overall Ranking # 364 # 405 # 384 # 306 # 365


Cumulative Revenue growth Comment
Assuming the Impel Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2023, Impel Pharmaceuticals Inc would have reprted above average annual Revenue surge of 149.81% year on year, of $ 21 millions.
This marks a slow-down of the companys growth trends and from the 259.96% surge in Jun 30 2023.

In the Healthcare sector 182 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 706, from total ranking in previous quarter at 796.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 183
Overall # 706

Revenue TTM Y/Y Growth Statistics
High Average Low
24.51 %
 12.27 %
0.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 116
S&P 500 # 364
Cumulative Revenue growth Comment
Assuming the Impel Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2023, Impel Pharmaceuticals Inc would have reprted above average annual Revenue surge of 149.81% year on year, of $ 21 millions.
This marks a slow-down of the companys growth trends and from the 259.96% surge in Jun 30 2023.

In the Healthcare sector 182 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 706, from total ranking in previous quarter at 796.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 183
Overall # 706

Revenue TTM Y/Y Growth Statistics
High Average Low
24.51 %
12.27 %
0.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 116
S&P 500 # 364




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMPL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Northwest Biotherapeutics Inc97.09%$ 97.087 millions
Revance Therapeutics Inc 95.68%$ 95.678 millions
Evoke Pharma Inc 87.82%$ 87.821 millions
Quantum Cyber N v 87.69%$ 87.692 millions
Xoma Royalty Corporation84.04%$ 84.035 millions
Proqr Therapeutics N v 82.00%$ 81.997 millions
Catalyst Pharmaceuticals Inc 79.39%$ 79.386 millions
Esperion Therapeutics Inc 78.97%$ 78.973 millions
Docgo Inc 78.83%$ 78.828 millions
Precision Biosciences Inc78.19%$ 78.188 millions
Marpai Inc76.77%$ 76.771 millions
Bicycle Therapeutics Plc76.05%$ 76.053 millions
Intra cellular Therapies Inc 75.56%$ 75.557 millions
Agilon Health Inc 74.95%$ 74.951 millions
Rxsight Inc 72.26%$ 72.263 millions
Elite Pharmaceuticals Inc 71.86%$ 71.860 millions
Procept Biorobotics Corporation71.38%$ 71.379 millions
Pacific Biosciences Of California Inc 69.92%$ 69.917 millions
Biocardia Inc 68.40%$ 68.396 millions
Xtant Medical Holdings Inc 68.26%$ 68.262 millions
Cvrx inc 67.98%$ 67.978 millions
Merus N v 67.65%$ 67.649 millions
Alimera Sciences Inc66.25%$ 66.245 millions
Castle Biosciences Inc 66.15%$ 66.148 millions
Coherus Oncology inc 64.16%$ 64.160 millions
C4 Therapeutics Inc 63.93%$ 63.932 millions
Y mabs Therapeutics inc 63.15%$ 63.149 millions
Nanostring Technologies Inc 62.79%$ 62.787 millions
Xeris Biopharma Holdings Inc 62.56%$ 62.557 millions
Avricore Health Inc 62.24%$ 62.240 millions


About Impel Pharmaceuticals Inc Revenue Growth Rates (IMPL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Impel Pharmaceuticals Inc (CIK 1445499).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-063759
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Impel Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.